Abramson Cancer Center of the University of Pennsylvania
Abramson Cancer Center of the University of Pennsylvania
Philadelphia, Pennsylvania, United States47 results · Page 1 of 2
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Neoadjuvant PD-1 Blockade in Patients With Stage IIB/C Melanoma | Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Skin and Connective Tissue Diseases, melanocytic neoplasm, melanoma, neoplasm, neuroendocrine neoplasm, primitive neuroectodermal tumor, skin disorder, skin neoplasm | Active, not recruiting | Phase 2 | 2026-10-09 | NCT03757689 | |
| Cardiotoxicity in Locally Advanced Lung Cancer Patients Treated With Chemoradiation Therapy | Cardiotoxicity, Chemically-Induced Disorders, Drug-Related Side Effects and Adverse Reactions, Neoplasms by Site, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Thoracic Neoplasms, cardiovascular disorder, heart disorder, injury, lung disorder, lung neoplasm, neoplasm, radiation injury, respiratory system disorder, respiratory tract neoplasm | Active, not recruiting | Not stated | 2026-10-05 | NCT04305613 | |
| Ovarian Tissue Transplantation | Infertile Females or Females With Ovarian Insufficiency | Recruiting | Not applicable | 2026-10-05 | NCT01870752 | |
| The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) | Adnexal Diseases, Biliary Tract Neoplasms, Digestive System Diseases, Digestive System Neoplasms, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Head and Neck Neoplasms, Male Urogenital Diseases, Neoplasm Metastasis, Neoplasms by Site, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Skin and Connective Tissue Diseases, Thoracic Neoplasms, Urogenital Diseases, Urogenital Neoplasms, biliary tract disorder, breast cancer, breast disorder, breast neoplasm, bronchial neoplasm, bronchogenic carcinoma, colonic disorder, colorectal cancer, colorectal neoplasm, digestive system disorder, digestive system neoplasm, endocrine system disorder, endometrium neoplasm, female reproductive system disorder, female reproductive system neoplasm, gallbladder disorder, gallbladder neoplasm, gonadal disorder, head and neck cancer, intestinal disorder, lung cancer, lung disorder, lung neoplasm, male reproductive organ cancer, male reproductive system disorder, malignant endocrine neoplasm, metastatic malignant neoplasm, neoplasm, non-small cell lung carcinoma, ovarian cancer, ovarian disorder, prostate cancer, prostate disorder, rectal disorder, respiratory system disorder, respiratory tract neoplasm, skin disorder, small cell lung carcinoma, triple-negative breast carcinoma, uterine disorder | Recruiting | Phase 1 / Phase 2 | 2026-10-02 | NCT04585750 | |
| The CArdiovascular Risk Evaluation in Men With Prostate Cancer Study (CARE-PC) Pilot Feasibility Study | Genital Diseases, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, male reproductive organ cancer, male reproductive system disorder, neoplasm, prostate cancer, prostate disorder | Active, not recruiting | Not applicable | 2026-09-25 | NCT06064149 | |
| Saruparib in HRDsig+ Solid Tumors | neoplasm | Not yet recruiting | Phase 2 | 2026-09-22 | NCT07832630 | |
| Investigation of β-hydroxybutyrate Supplementation as Chemoprevention in Familial Adenomatous Polyposis | Adenomatous Polyps, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Cronkhite-Canada syndrome, Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Pathological Conditions, Anatomical, Pathological Conditions, Signs and Symptoms, adenoma, classic familial adenomatous polyposis, colonic disorder, colorectal neoplasm, digestive system disorder, digestive system neoplasm, epithelial neoplasm, hereditary disease, hereditary neoplastic syndrome, intestinal disorder, neoplasm, polyp | Enrolling by invitation | Not applicable | 2026-09-16 | NCT06578637 | |
| CAR-T Followed by Bispecific Antibodies | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, histiocytosis, interdigitating dendritic cell sarcoma, large B-cell lymphoma, lymphatic system disorder, malignant histiocytosis, neoplasm | Active, not recruiting | Phase 2 | 2026-09-14 | NCT04889716 | |
| Phase I Pilot Study of Biodistribution, Metabolism and Excretion of Novel Radiotracer [18F]Fluorthanatrace (FTT) by PET/CT | Suspected Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | Active, not recruiting | Phase 1 | 2026-09-02 | NCT02637934 | |
| A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas | B-cell neoplasm, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Hemic and Lymphatic Diseases, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Prostatic Neoplasms, Castration-Resistant, T-cell non-Hodgkin lymphoma, Thoracic Neoplasms, Urogenital Diseases, Urogenital Neoplasms, adenoma, diffuse large B-cell lymphoma, endometrium neoplasm, epithelial neoplasm, female reproductive system disorder, female reproductive system neoplasm, immune system disorder, immunoproliferative disorder, lung disorder, lung neoplasm, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, male reproductive organ cancer, male reproductive system disorder, malignant mesothelioma, mesothelial neoplasm, mesothelioma, neoplasm, pleural neoplasm, prostate cancer, prostate disorder, respiratory system disorder, respiratory tract neoplasm, uterine disorder | Recruiting | Phase 1 / Phase 2 | 2026-08-19 | NCT04104776 | |
| PENN-Surveillance Markers of Utility for Recurrence After (Neo)Adjuvant Therapy for Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorder | Recruiting | Not applicable | 2026-08-19 | NCT02732171 | |
| Preliminary Investigation of β-hydroxybutyrate Supplementation in Colorectal Cancer Prevention | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, colonic disorder, colorectal cancer, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, neoplasm, rectal disorder | Active, not recruiting | Not applicable | 2026-08-12 | NCT05338307 | |
| Frailty Phenotype Assessments to Optimize Treatment Strategies for Older Patients With Hematologic Malignancies | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, hematologic disorder, leukemia, myelodysplastic syndrome, neoplasm | Recruiting | Not stated | 2026-08-12 | NCT03680677 | |
| A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01) | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder, triple-negative breast carcinoma | Recruiting | Phase 2 / Phase 3 | 2026-08-10 | NCT06926868 | |
| TmPSMA-02 in mCRPC | Metastatic Castrate-Resistant Prostate Cancer (mCRPC) | Active, not recruiting | Phase 1 | 2026-08-10 | NCT06046040 | |
| The Breast Program - Translational Cancer Resource | Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorder | Active, not recruiting | Not stated | 2026-08-05 | NCT02798341 | |
| Mild Hypofractionation With Proton Therapy or IMRT for Intermediate-Risk Prostate Cancer | prostate adenocarcinoma | Active, not recruiting | Not stated | 2026-07-22 | NCT01352429 | |
| Phase 1b/2 Trial of Ipilimumab, Nivolumab, and Ciforadenant (Adenosine A2a Receptor Antagonist) in First-line Advanced Renal Cell Carcinoma. | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, adenocarcinoma, benign urinary system neoplasm, carcinoma, epithelial neoplasm, kidney cancer, kidney disorder, neoplasm, renal cell carcinoma, urinary system disorder | Active, not recruiting | Phase 1 / Phase 2 | 2026-07-16 | NCT05501054 | |
| PICSTAT Pilot Study for CD8 PET/CT-Guided Lifileucel Treatment in Advanced Melanoma | Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Skin and Connective Tissue Diseases, melanocytic neoplasm, melanoma, neoplasm, neuroendocrine neoplasm, primitive neuroectodermal tumor, skin disorder, skin neoplasm | Not yet recruiting | Early phase 1 | 2026-07-13 | NCT07700121 | |
| Evaluating in Vivo PARP-1 Expression With 18F-FluorThanatrace Positron Emission Tomography (PET/CT) in Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorder | Active, not recruiting | Phase 1 | 2026-07-13 | NCT03083288 | |
| QuantifyHER: Quantitative Immunofluorescence and/or RT-qPCR for Measuring HER2 in HER2-low Metastatic Breast Cancer | HER2-positive Metastatic Breast Cancer | Recruiting | Not stated | 2026-07-08 | NCT06551116 | |
| Prospective Follow-up of Outcomes in Patients Receiving Photodynamic Therapy for Neoplastic Diseases | neoplasm | Active, not recruiting | Not stated | 2026-07-08 | NCT02159742 | |
| Protocol to Permit the Acquisition of Circulating Tumor Material in Pancreatic Diseases | Digestive System Diseases, pancreas disorder | Enrolling by invitation | Not stated | 2026-07-02 | NCT02471170 | |
| CLEVER Pilot Trial: A Phase II Pilot Trial of HydroxyChLoroquine, EVErolimus or the Combination for Prevention of Recurrent Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder | Active, not recruiting | Phase 2 | 2026-06-29 | NCT03032406 | |
| Itacitinib + Everolimus in Hodgkin Lymphoma | classic Hodgkin lymphoma | Active, not recruiting | Phase 1 / Phase 2 | 2026-06-23 | NCT03697408 |